BACKGROUND AND OBJECTIVE: This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation. METHODS: For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. KEY FINDINGS AND LIMITATIONS: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice.

Department of Pathology Medical University of Vienna Vienna Austria

Department of Surgical Oncology Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam The Netherlands

Department of Urology APHP Saint Louis Hospital Université de Paris Paris France

Department of Urology Bichat Claude Bernard Hospital AP HP Université de Paris Paris France

Department of Urology Città della Salute e della Scienza University of Torino School of Medicine Torino Italy

Department of Urology Comprehensive Cancer Center Vienna General Hospital Medical University Vienna Vienna Austria

Department of Urology Freeman Hospital The Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK

Department of Urology Fundación Instituto Valenciano de Oncología Valencia Spain

Department of Urology General Teaching Hospital and 1st Faculty of Medicine Charles University Praha Prague Czech Republic

Department of Urology La Croix Du Sud Hospital Quint Fonsegrives France

Department of Urology The Stokes Centre for Urology Royal Surrey Hospital Guildford UK

EAU Guidelines Office Arnhem The Netherlands

Edinburgh Bladder Cancer Surgery Western General Hospital The University of Edinburgh Edinburgh UK

Institute of Translational Medicine Lund University Malmö Sweden; Department of Urology Skåne University Hospital Malmö Sweden

Rosemere Cancer Centre Lancashire Teaching Hospitals NHS Foundation Trust Preston UK

Urology GRC 5 Predictive Onco Uro AP HP Pitie Salpetriere Hospital Sorbonne University Paris France

Citace poskytuje Crossref.org